Navigation Links
New Study Shares Benchmarks for Fixed-Dose Combination (FDC) Drug Development
Date:2/5/2009

CHAPEL HILL, N.C., Feb. 5 /PRNewswire/ -- As biopharmaceutical companies focus on line extensions and new product development opportunities, fixed-dose combination (FDC) products have become an increasingly important segment of the market. In an effort to better understand the development strategies and issues for new FDC products, a recent study was conducted by Best Practices, LLC, with insights available in the newly published report, "Product Commercialization Excellence: Preparation and Management of Fixed-dose Combination (FDC) Drug Products." The research explored a number of critical questions, including: whether organizations seek additive or synergistic FDC drugs; why companies chose either a bioequivalence or clinical evaluation approach; and whether organizations are using external consultants and for what purposes.

Among the many benchmarks included in this study are timeframes for both bioequivalence and clinical evaluation development approaches and the number, types and frequency of tests required. Executives who are responsible for fixed-dose combination (FDC) drug development can use this data to assess the effectiveness and efficiency of their FDC drug product development programs.

To view the study abstract or complimentary summary of the full report "Product Commercialization Excellence: Preparation and Management of Fixed-dose Combination (FDC) Drug Products," click on the following link http://www3.best-in-class.com/re938.htm .

In a benchmarking study that included such influential companies as Abbott, Bayer, Roche, Merck, Pfizer, and Sanofi-Aventis, many key topics were covered, including:

    -- Bioequivalence Approach
    -- Clinical Evaluation Approach
    -- Lessons Learned
    -- FTEs and Complexity


    Among the key metrics gathered in this report are:
    -- Past, Present and Future Number of FDC Drugs in Development
    -- Additive vs. Synergistic Effects
    -- Bioequivalence vs. Clinical Evaluation (Preferences and reasons why)
    -- Starting Development Prior vs. Post Patent Expiration
    -- Use of External Consultants
    -- Bioequivalence -- Timeframe from Conception to Final Formulation Launch
    -- Clinical Evaluation -- Timeframe from Conception to Final Formulation
       Launch
    -- Bioequivalence -- Timeframe from Initiating Formulation Development to
       Final Formulation Launch
    -- Clinical Evaluation -- Timeframe from Initiating Formulation
       Development to Final Formulation Launch
    -- Bioequivalence -- Multiple Metrics
    -- Clinical Evaluation -- Multiple Metrics
    -- Number of Drugs, FTEs and Timeframe to Reach First/Second Pilot PK
       Study
    -- Number of Drugs, FTEs and Timeframe to Reach Pivotal BE Study
    -- Number of FTEs in Analytical Development
    -- Timeframe from Initiating Development Work to CTM Manufacturing for
       Class 1/2/4 drugs

For more information on this study or the Best Practices, contact Ben Gregory at bgregory@best-in-class.com or (919) 767-9160. To access a full copy of the report or download a free excerpt, click the following link: http://www3.best-in-class.com/re938.htm .

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research exclusively for our Fortune 500 client base.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. New Study Provides Benchmarks for Optimizing Marketing Staff Levels to Drive Growth
2. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
3. Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
4. New Study Provides Benchmarks for Winning Brand Team Management
5. New Study Shares Insights for Competitive Intelligence Policies, Ethics and Data Collection
6. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
7. Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy
8. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
9. Clinical Research Study Focuses on Little Known Behavioral Changes Related to Parkinsons Disease
10. Cardiovascular Side Effects of Pioglitazone and Rosiglitazone Linked to Vascular and Energy Pathways by Genomas Clinical Study
11. Genomic Health Announces Commencement of QUASAR Clinical Validation Study for Oncotype DX(R) Colon Cancer Assay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... ... of Tom Perkins as European director. Operating from Pennside’s Zurich headquarters, Pennside Partners, ... , Perkins joins Pennside after more than a decade with leading market research ...
(Date:2/22/2017)... SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., ... UTHR ) today announced its financial results ... 2016. "Our annual 2016 financial results ... billion and earnings exceeded $700 million," said Martine ... Officer. "These financial results strengthen our ability to ...
(Date:2/21/2017)... Inc. ("SQI" or the "Company") (TSX-V: SQD; OTCQX: SQIDF), today reported ... December 31, 2016. SQI is a ... develops and commercializes proprietary technologies and products for advanced multiplexed ... ... in fiscal 2016," said Andrew Morris , SQI,s President ...
(Date:2/21/2017)... ... February 21, 2017 , ... Vortex ... , a fully automated benchtop system for collecting intact circulating tumor cells (CTCs) ... at the Molecular Medicine Tri Conference (Tri-Con) Annual Meeting 2017 (February 19–24 San ...
Breaking Biology Technology:
(Date:2/14/2017)... WINSTON-SALEM, N.C. , Feb. 14, 2017  Wake ... FRY-shlog), M.D., as its new chief executive officer (CEO). ... succeeds CEO John D. McConnell , M.D., who ... new position at the Medical Center, after leading it ... oversee the full scope of Wake Forest Baptist,s academic ...
(Date:2/8/2017)... , Feb. 8, 2017 About Voice ... voice to match it against a stored voiceprint ... as pitch, cadence, and tone are compared to ... minimal hardware installation, as most PCs already have ... different transactions. Voice recognition biometrics are most likely ...
(Date:2/7/2017)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the latest release of ... and award winning eClinical solution, is now available for ... a proven Software-as-a-Service (SaaS) clinical research technology platform that ... delivers an entire suite of eClinical tools to support ...
Breaking Biology News(10 mins):